According to Grigson, Because our preliminary data suggested that patients did better in the study if they were on both the GLP-1 drug and medication for opioid use disorder, in this study, half of the participants will be on methadone and half will be on buprenorphine for opioid use disorder treatment. Because semaglutide is stronger, is dosed weekly instead of daily, and has fewer gastrointestinal side effects than liraglutide, it may be even more effective in reducing craving while increasing real-world treatment adherence
Antioxidants 10(6):967 Wells G, Shea B, OConnell D, Peterson J, Welch V, Losos M, Tugwell P (2021) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
In 2026, the Blood in Stool ICD 10 code you select determines the financial health of your gastrointestinal practice
The high price of GLP-1 drugs could be substantially reduced in the future once they come off patent thereby allowing for the introduction of biosimilars